Multiple less common genetic variants explain the association of the cholesteryl ester transfer protein gene with coronary artery disease.

OBJECTIVES The objective of this study was to identify associations of the cholesteryl ester transfer protein (CETP) gene with coronary artery disease (CAD) with tagging (t) single nucleotide polymorphisms (SNPs) chosen to optimally account for intra-genic variation. BACKGROUND The CETP gene plays a critical role in lipoprotein metabolism, but the common and well-studied TaqIB variant is inconsistently predictive of CAD. METHODS From a deoxyribonucleic acid bank of 10,020 individuals, nondiabetic nonsmoking patients (n = 4,811) with angiographically defined, clinically significant CAD (> or =70% stenosis) or normal coronaries were genotyped for 11 CETP tSNPs. Myocardial infarction (MI) and lipid levels were evaluated as secondary end points. RESULTS Analysis of single tSNPs, corrected for multiple comparisons (p < 0.00485), identified allele +1086A to be associated with CAD (p = 0.0034). Suggestive allelic and significant genotypic associations were found for -631AA (odds ratio [OR] = 3.95, p = 0.004 vs. CC) and +2389GA (OR = 1.21, p = 0.003 vs. GG). Haplotype analysis by linkage disequilibrium (LD) group revealed a CAD association for LD group B (p = 0.0025 across T+1086A, C+878T, C+408T) and near significance for LD group A (p = 0.013 across C-631A, MspI, G+2389A). A weak protective trend for TaqIB was eliminated by adjustment for other tSNPs, and haplotype analyses suggested that TaqIB was simply a marker for other tSNPs or haplotypes. No tSNP or haplotype associations with MI were found. CONCLUSIONS Multiple, less common SNPs and haplotype variants underlie CETP-related CAD risk, for which the common TaqIB variant is simply a poor marker. The occurrence of risk-related variants on separate haplotypes suggests genetic-risk complexity and allelic heterogeneity. (Database Registry of the Intermountain Heart Collaborative Study; http://clinicaltrials.gov/ct/show/NCT00406185?order=1; NCT00406185).

[1]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[2]  B. Horne,et al.  Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early‐onset prostate cancer , 2005, Genetic epidemiology.

[3]  Johnf . Thompson,et al.  Polymorphisms in the CETP gene and association with CETP mass and HDL levels. , 2003, Atherosclerosis.

[4]  Jonathan C. Cohen,et al.  Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.

[5]  R. Peters,et al.  Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk Population Study , 2004, Circulation.

[6]  M. Olivier.  A haplotype map of the human genome. , 2003, Nature.

[7]  R. Hegele.  SNP judgments and freedom of association. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Tall.  Plasma lipid transfer proteins. , 1986, Journal of lipid research.

[9]  Riitta Veijola,et al.  Haplotype structure, LD blocks, and uneven recombination within the LRP5 gene. , 2003, Genome research.

[10]  N J Camp,et al.  Generating Genetic Risk Scores from Intermediate Phenotypes for Use in Association Studies of Clinically Significant Endpoints , 2005, Annals of human genetics.

[11]  J. Boer,et al.  Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[12]  E. Topol,et al.  Genetic susceptibility to myocardial infarction and coronary artery disease. , 2006, Human molecular genetics.

[13]  P J Talmud,et al.  Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects , 2005, Circulation.

[14]  B. Horne,et al.  Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. , 2005, American heart journal.

[15]  A polymorphism of the cholesterol ester transfer protein gene predicts cardiovascular events in non-smokers in the west of scotland coronary prevention study , 2004 .

[16]  A. Yashin,et al.  Heritability of death from coronary heart disease: a 36‐year follow‐up of 20 966 Swedish twins , 2002, Journal of internal medicine.

[17]  J. Terwilliger,et al.  An utter refutation of the ‘Fundamental Theorem of the HapMap’ , 2006, European Journal of Human Genetics.

[18]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[19]  D. Rader,et al.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.

[20]  B. Horne,et al.  High‐Resolution Characterization of Linkage Disequilibrium Structure and Selection of Tagging Single Nucleotide Polymorphisms: Application to the Cholesteryl Ester Transfer Protein Gene , 2006, Annals of human genetics.

[21]  B. Horne,et al.  The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. , 2003, American heart journal.

[22]  E. Lander.  The New Genomics: Global Views of Biology , 1996, Science.

[23]  B. Nordestgaard,et al.  Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease: The Copenhagen City Heart Study , 2000, Circulation.

[24]  R. Pyeritz.  Family history and genetic risk factors: forward to the future. , 1997, JAMA.

[25]  G. Jensen,et al.  Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. , 2000, Circulation.

[26]  J. Carlquist,et al.  Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: do they add up yet? , 2003, Journal of the American College of Cardiology.

[27]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[28]  B. Horne,et al.  Principal component analysis for selection of optimal SNP‐sets that capture intragenic genetic variation , 2004, Genetic epidemiology.

[29]  Johnf . Thompson,et al.  CETP polymorphisms associated with HDL cholesterol may differ from those associated with cardiovascular disease. , 2005, Atherosclerosis.

[30]  Generating Genetic Risk Scores from Intermediate Phenotypes for Use in Association Studies of Clinically Significant Endpoints , 2005 .

[31]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[32]  K. Weiss,et al.  How many diseases does it take to map a gene with SNPs? , 2000, Nature Genetics.

[33]  J Wouter Jukema,et al.  Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. , 2005, Human molecular genetics.

[34]  A. Zwinderman,et al.  Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration. , 2003, Human molecular genetics.

[35]  Frank Dudbridge,et al.  Haplotype tagging for the identification of common disease genes , 2001, Nature Genetics.

[36]  Sarah Parish,et al.  Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls , 1999, The Lancet.

[37]  J. Carlquist,et al.  Cardiovascular Pharmacogenomics: Current Status, Future Prospects , 2003, Journal of cardiovascular pharmacology and therapeutics.